Literature DB >> 19958892

Discrepancies between office and ambulatory blood pressure: clinical implications.

José R Banegas1, Franz H Messerli, Bernard Waeber, Fernando Rodríguez-Artalejo, Alex de la Sierra, Julián Segura, Alex Roca-Cusachs, Pedro Aranda, Luis M Ruilope.   

Abstract

BACKGROUND: Recent trials have documented no benefit from small reductions in blood pressure measured in the clinical office. However, ambulatory blood pressure is a better predictor of cardiovascular events than office-based blood pressure. We assessed control of ambulatory blood pressure in treated hypertensive patients at high cardiovascular risk.
METHODS: We selected 4729 patients from the Spanish Ambulatory Blood Pressure Monitoring Registry. Patients were aged >/=55 years and presented with at least one of the following co-morbidities: coronary heart disease, stroke, and diabetes with end-organ damage. An average of 2 measures of blood pressure in the office was used for analyses. Also, 24-hour ambulatory blood pressure was recorded at 20-minute intervals with a SpaceLabs 90207 device.
RESULTS: Patients had a mean age of 69.6 (+/-8.2) years, and 60.8% of them were male. Average time from the diagnosis of hypertension to recruitment into the Registry was 10.9 (+/-8.4) years. Mean blood pressure in the office was 152.3/82.3 mm Hg, and mean 24-hour ambulatory blood pressure was 133.3/72.4 mm Hg. About 60% of patients with an office-pressure of 130-139/85-89 mm Hg, 42.4% with office-pressure of 140-159/90-99 mm Hg, and 23.3% with office-pressure > or =160/100 mm Hg were actually normotensive, according to 24-hour ambulatory blood pressure criteria (<130/80 mm Hg).
CONCLUSION: We suggest that the lack of benefit of antihypertensive therapy in some trials may partly be due to some patients having normal pressure at trial baseline. Ambulatory monitoring of blood pressure may allow for a better assessment of trial eligibility.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958892     DOI: 10.1016/j.amjmed.2009.05.020

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

Review 1.  The evolution and refinement of traditional risk factors for cardiovascular disease.

Authors:  Emil M deGoma; Joshua W Knowles; Fabio Angeli; Matthew J Budoff; Daniel J Rader
Journal:  Cardiol Rev       Date:  2012 May-Jun       Impact factor: 2.644

Review 2.  Current challenges in the clinical management of hypertension.

Authors:  Luis M Ruilope
Journal:  Nat Rev Cardiol       Date:  2011-10-25       Impact factor: 32.419

3.  Effect of continuous positive airway pressure treatment on ambulatory blood pressures in high-risk sleep apnea patients: a randomized controlled trial.

Authors:  Ying Y Zhao; Rui Wang; Kevin J Gleason; Eldrin F Lewis; Stuart F Quan; Claudia M Toth; Yue Song; Michael Morrical; Michael Rueschman; Murray A Mittleman; Susan Redline
Journal:  J Clin Sleep Med       Date:  2022-08-01       Impact factor: 4.324

4.  Recent advances in the management of hypertension.

Authors:  José Antonio García-Donaire; Luis M Ruilope
Journal:  F1000 Med Rep       Date:  2010-03-15

5.  Magnitude of the Difference Between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Patients With Chronic Kidney Disease.

Authors:  Elaine Ku; Raymond K Hsu; Delphine S Tuot; Se Ri Bae; Michael S Lipkowitz; Miroslaw J Smogorzewski; Barbara A Grimes; Matthew R Weir
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

6.  Prevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy.

Authors:  Faiez Zannad; Jean Dallongeville; Robert J Macfadyen; Luis M Ruilope; Lars Wilhelmsen; Guy De Backer; Ian Graham; Matthias Lorenz; Giuseppe Mancia; David A Morrow; Zeljko Reiner; Wolfgang Koenig
Journal:  Eur J Prev Cardiol       Date:  2012-12       Impact factor: 7.804

7.  Pre-hypertension: another 'pseudodisease'?

Authors:  Pascal Meier; Franz H Messerli; Andreas Baumbach; Alexandra J Lansky
Journal:  BMC Med       Date:  2013-09-25       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.